---
title: "The cancer pathology gene large model DeepGEM is implemented"
description: "On October 23rd, reporters learned from Guangzhou KingMed Diagnostics Group Co., Ltd. that the cancer pathology gene large model DeepGEM has recently been deployed at the company. Relying on this larg"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262788924.md"
published_at: "2025-10-26T23:52:41.000Z"
---

# The cancer pathology gene large model DeepGEM is implemented

> On October 23rd, reporters learned from Guangzhou KingMed Diagnostics Group Co., Ltd. that the cancer pathology gene large model DeepGEM has recently been deployed at the company. Relying on this large model, the company will collaborate with Tencent and the First Affiliated Hospital of Guangzhou Medical University to jointly develop a multimodal large model for pathological genes, allowing accurate, timely, and accessible new gene mutation prediction technologies to benefit more cancer patients

On October 23rd, reporters learned from Guangzhou Kingmed Diagnostics Group Co., Ltd. that the cancer pathology gene large model DeepGEM has recently been deployed at the company. Relying on this large model, the company will collaborate with Tencent and the First Affiliated Hospital of Guangzhou Medical University to jointly develop a multimodal large model for pathological genes, allowing accurate, timely, and accessible gene mutation prediction technologies to benefit more cancer patients

### Related Stocks

- [TCEHY.US - Tencent](https://longbridge.com/en/quote/TCEHY.US.md)
- [TCTZF.US - Tencent Holdings Limited](https://longbridge.com/en/quote/TCTZF.US.md)
- [00700.HK - TENCENT](https://longbridge.com/en/quote/00700.HK.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 18:01 ETBreakthrough Study Confirms HYD LLC's 30-Year Research on Deuterium Modulation in Cancer Gene Expression | A new study published in the International Journal of Molecular Sciences confirms HYD LLC's 30-year research on deuteriu | [Link](https://longbridge.com/en/news/275953157.md) |
| 11:03 ETNew Guidelines from NCCN Detail Fundamental Differences in Cancer in Children Compared to Adults | The National Comprehensive Cancer Network (NCCN) has released new Clinical Practice Guidelines for Pediatric Soft Tissue | [Link](https://longbridge.com/en/news/276145789.md) |
| 10:02 ETThe Center for Cancer and Blood Disorders Revolutionizes the Delivery of CAR-T Cancer Treatments for Texas Patients | The Center for Cancer and Blood Disorders has launched a program to deliver CAR-T therapy in community practices across  | [Link](https://longbridge.com/en/news/276139832.md) |
| Aprea Therapeutics Advanced Cancer Trial Shows Promising Results, Stock Soars | Aprea Therapeutics shares surged 16.62% to $0.70 following promising Phase 1 trial results for APR-1051, a WEE1 kinase i | [Link](https://longbridge.com/en/news/276264904.md) |
| Grail Stock Is Deeply Oversold on Cancer Test Failings. Is There Any Hope Left to Buy the Dip? | Grail Stock Is Deeply Oversold on Cancer Test Failings. Is There Any Hope Left to Buy the Dip? | [Link](https://longbridge.com/en/news/276486904.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.